Maine Issued Advisory After Dangerous Butane Levels Found
State officials warned medical cannabis patients about high solvent levels following reports of adverse health reactions.
Updated on Sept. 21, 2026 in Substance Abuse
Live Poll
Should medical cannabis products be required to undergo the same safety testing as adult-use cannabis?
The Maine Office of Cannabis Policy issued a safety advisory after two patients reported adverse health reactions linked to cannabis concentrates from Ganja World. Testing of the Deep Sea strain revealed butane levels significantly exceeding standard safety thresholds.
Why it matters
This incident highlights a critical gap in medical cannabis oversight in Maine, where operators are not required to conduct mandatory contaminant testing. Because the state lacks the legal authority to force recalls in the medical program, patients must rely on these state-issued warnings.
Official testing confirmed the Deep Sea strain contained butane levels up to twice the 5,000 ppm threshold permitted in Maine’s adult-use program. This finding followed reports of adverse health reactions from two patients, though mandatory contaminant testing is currently not required for medical operators.
The players
Maine Office of Cannabis Policy
The state agency responsible for overseeing and regulating the use of medical and adult-use cannabis.
Ganja World
A cannabis provider whose products were linked to patient reports of adverse health reactions.
The details
Butane is a solvent used to extract cannabinoids from plant material, but it can leave hazardous residues if the purging process is insufficient. Excessive inhalation of butane may lead to adverse health reactions, as indicated by the patient complaints investigated by the Maine Office of Cannabis Policy. The state is now working to identify the specific source of the contamination at the Ganja World facility.
Timeline
Late August 2026: Two patients filed complaints regarding adverse reactions.
September 18, 2026: The Maine Office of Cannabis Policy issued a medical cannabis patient advisory.
Health Landscape
This incident draws attention to the regulatory disparity between Maine's adult-use and medical cannabis markets, particularly regarding mandatory safety protocols. It highlights the vulnerability of patients in programs where contaminant testing is not enforced by law.
If you have purchased cannabis concentrate from Ganja World, stop using it immediately and consult your physician if you experience any adverse symptoms. Always discuss concerns about product safety or sourcing with your healthcare provider to ensure you are accessing safe, tested medication.
The takeaway
Patients using cannabis concentrates should be aware that medical products may not undergo the same mandatory safety testing as adult-use versions. If you have questions about the safety or testing history of your specific medical cannabis, contact the dispensary to request a certificate of analysis.
Further reading
For more information on state safety standards, visit Substance Abuse.
Source note: This article includes information reported by Cannabis Business Times.
Live Poll
Should medical cannabis products be required to undergo the same safety testing as adult-use cannabis?
